title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,BTAI,0.006905,Neutral,-0.008017
Stocks That Hit 52-Week Lows On Thursday,20220421T175401,https://www.benzinga.com/markets/options/22/04/26742233/52-weeks-high-and-low-article,BTAI,0.021637,Neutral,0.002113
"The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs",20220503T130106,https://www.benzinga.com/general/biotech/22/05/26958446/the-daily-biotech-pulse-fdas-adcomm-for-acadias-pimavanserin-review-issues-for-speros-tebipenem-a,BTAI,0.093507,Neutral,0.006528
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,BTAI,0.025139,Neutral,0.05757
